Jeffrey A. Allen

Jeffrey A. Allen

Neurology | Neuromusculoskeletal Medicine
909 Fulton Street Southeast
Floor 3
Minneapolis, MN 55455

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Journal: Neurology
Published: June 16, 2026

FcRn inhibitors in the treatment of CIDP.

FcRn inhibitors in the treatment of CIDP.

Journal: Journal of the neurological sciences
Published: May 22, 2026

The MuFusE large-volume diamond anvil cell for exploring muon-catalyzed fusion at higher pressures and temperatures.

The MuFusE large-volume diamond anvil cell for exploring muon-catalyzed fusion at higher pressures and temperatures.

Journal: The Review of scientific instruments
Published: April 06, 2026

Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis.

Long-Term Safety and Efficacy of Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis.

Journal: Journal of the peripheral nervous system : JPNS
Published: March 19, 2026

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial.

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial.

Journal: Therapeutic advances in neurological disorders
Published: August 18, 2025

Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Journal: Journal of the peripheral nervous system : JPNS
Published: June 03, 2025

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Journal: Expert review of clinical immunology
Published: April 29, 2025

Feasibility and Reliability of a Monitoring App for Chronic Inflammatory Neuropathies.

Feasibility and Reliability of a Monitoring App for Chronic Inflammatory Neuropathies.

Journal: Journal of the peripheral nervous system : JPNS
Published: October 23, 2024

Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

Journal: Journal of the peripheral nervous system : JPNS
Published: October 06, 2024

New chronic inflammatory demyelinating polyneuropathy/Guillain-Barré syndrome guidelines - impact on clinical practise.

New chronic inflammatory demyelinating polyneuropathy/Guillain-Barré syndrome guidelines - impact on clinical practise.

Journal: Current opinion in neurology
Published: June 14, 2024

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Journal: The Lancet. Neurology
Published: May 14, 2024

Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy.

Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy.

Journal: BMC neurology
Published: April 05, 2024
Showing 1-12 of 62

Last Updated: 09/26/2026